XVIVO Perfusion reports Q3 2026 net sales of SEK 252.6M, up 34%

XVIVO Perfusion AB reported Q3 2026 net sales of SEK 252.6 million, up 34% year over year, with operating income (EBIT) of SEK 28.0 million and EBITDA of SEK 52.0 million. The company also secured CE marking for its XVIVO Heart Assist Transport, enabling commercial availability in Europe, and reported positive one-year follow-up results from its European multicenter heart trial.

Detected & updated continuously · Source: Nebula